A 42-year-old woman presents to her GP describing persistent low mood, early morning wakening, and loss of interest in activities she once enjoyed. She's unsure whether she's "just stressed" or whether something more significant is wrong. This scenario exemplifies the diagnostic challenge of common mental disorders-conditions that are simultaneously prevalent, debilitating, and often under-recognised. Understanding the core features of depression , generalised anxiety disorder , and panic disorder is essential for accurate identification and timely intervention in primary care settings.
Depression: Characterised by persistent low mood and/or anhedonia lasting ≥2 weeks, with associated biological and cognitive symptoms
Generalised Anxiety Disorder (GAD): Excessive, uncontrollable worry about multiple domains for ≥6 months
Panic Disorder: Recurrent unexpected panic attacks with persistent concern about future attacks
📌 Mnemonic for Depression (DSM-5 criteria): SIG E CAPS
Sleep disturbance, Interest loss, Guilt/worthlessness, Energy deficit, Concentration impairment, Appetite change, Psychomotor changes, Suicidal ideation
| Disorder | Core Features | Duration Threshold | Severity Markers |
|---|---|---|---|
| Depression | Low mood + anhedonia | ≥2 weeks | Suicidal ideation, psychotic features, severe functional impairment |
| GAD | Excessive worry + physical tension | ≥6 months | Worry >50% of days, multiple domains affected |
| Panic Disorder | Recurrent panic attacks | ≥1 month of concern/behavioural change | Agoraphobic avoidance, frequency >2/week |


The monoamine hypothesis, while oversimplified, remains clinically useful for understanding antidepressant mechanisms in depression . Reduced synaptic availability of serotonin, noradrenaline, and dopamine in key neural circuits-particularly the prefrontal cortex, hippocampus, and amygdala-correlates with depressive symptoms. However, neuroplasticity changes, including reduced hippocampal neurogenesis and disrupted HPA axis regulation, better explain why antidepressants require 4-6 weeks for clinical effect despite immediate monoamine elevation.
Depression neurobiology:
GAD neurobiological mechanisms :
Symptom cluster differentiation:
| Neurotransmitter | Depression Role | Anxiety Role | Therapeutic Target |
|---|---|---|---|
| Serotonin (5-HT) | Mood, sleep, appetite regulation | Worry modulation, threat processing | SSRIs, SNRIs |
| Noradrenaline (NA) | Energy, motivation, concentration | Arousal, vigilance | SNRIs, TCAs |
| GABA | Reduced in severe depression | Primary inhibitory deficit in GAD | Benzodiazepines (short-term) |
A 28-year-old man presents with palpitations, chest tightness, and fear of dying. He's attended A&E three times in the past month with normal ECGs and troponins. This presentation pattern-recurrent physical symptoms with negative investigations-should trigger consideration of panic disorder . NICE NG222 recommends structured assessment tools to standardise diagnosis and monitor treatment response in primary care.
Validated screening instruments:
Diagnostic hierarchy considerations:
Red flags requiring urgent psychiatric assessment 🚩:
| Assessment Tool | Score Range | Clinical Action Threshold | Monitoring Frequency |
|---|---|---|---|
| PHQ-9 | 0-27 | ≥10: Consider treatment | Every 2-4 weeks during active treatment |
| GAD-7 | 0-21 | ≥8: Probable anxiety disorder | Every 4 weeks initially |
| Columbia Suicide Severity Rating Scale | N/A | Any ideation with plan/intent | Every contact if risk identified |

Distinguishing between depression and GAD presents a common clinical challenge, particularly given their 50-60% comorbidity rate. The key discriminator lies not in the presence of worry-which occurs in both-but in its quality and associated features. In depression, worry is typically past-focused, ruminative, and centred on themes of failure or worthlessness. In GAD, worry is future-oriented, uncontrollable, and spans multiple domains (health, finances, relationships, work).
Depression vs GAD key differentiators:
Panic disorder vs cardiac disease :
Bipolar disorder screening in apparent depression:
| Feature | Depression | GAD | Panic Disorder |
|---|---|---|---|
| Core emotion | Sadness, emptiness | Apprehension, tension | Acute terror |
| Cognitive focus | Past failures, guilt | Future threats | Immediate catastrophe |
| Physical symptoms | Fatigue, appetite/sleep change | Muscle tension, restlessness | Discrete episodes: palpitations, breathlessness |
| Time course | Persistent (weeks-months) | Chronic fluctuating (months-years) | Episodic (minutes-hours) |
| Response to reassurance | Minimal | Temporary | Brief |
⭐ Clinical Pearl: If a patient describes worry as "stuck on a loop" they can't stop despite recognizing it's excessive, think GAD. If they describe feeling "empty" or "nothing matters anymore," think depression.
NICE NG222 advocates a stepped-care approach for depression and anxiety disorders , matching intervention intensity to severity and treatment response. For mild depression (PHQ-9 10-15), initial management should include psychoeducation, sleep hygiene, and structured physical activity (150 minutes moderate-intensity exercise weekly), with watchful waiting for 2 weeks before escalating. Moderate-to-severe depression (PHQ-9 ≥16) warrants first-line pharmacological or high-intensity psychological intervention.
First-line antidepressant therapy:
GAD pharmacological management:
Panic disorder specific considerations:
When to escalate care:
| Medication | Starting Dose | Target Dose | Key Monitoring | Common Adverse Effects |
|---|---|---|---|---|
| Sertraline | 50mg OD | 100-200mg OD | Suicidal ideation, GI symptoms | Nausea, diarrhoea, sexual dysfunction |
| Citalopram | 20mg OD | 20-40mg OD (max 40mg) | QTc if cardiac risk factors | Drowsiness, sexual dysfunction |
| Venlafaxine XL | 75mg OD | 150-225mg OD | BP (dose-dependent ↑) | Nausea, sweating, withdrawal if stopped abruptly |
| Mirtazapine | 15mg nocte | 30-45mg nocte | Weight, sedation | Weight gain, sedation (paradoxically less at higher doses) |
A 55-year-old woman with depression has tried three SSRIs sequentially without significant improvement. She has comorbid type 2 diabetes, takes metformin and atorvastatin, and describes her mood as "flat" with profound fatigue. This scenario requires synthesis of multiple factors: treatment resistance definition (failure of ≥2 adequate trials), medical comorbidity impact, and potential need for specialist intervention. NICE NG222 recommends considering augmentation strategies or switching to different mechanistic classes before labelling true treatment resistance.
Defining inadequate response:
Augmentation strategies for depression:
Special population considerations:
GAD treatment resistance :
| Clinical Scenario | Adjustment Strategy | Evidence Level | Monitoring Requirements |
|---|---|---|---|
| SSRI partial response | Add mirtazapine 15-30mg nocte | Moderate (RCT evidence) | Weight, lipids, sedation |
| SSRI + SNRI failure | Switch to mirtazapine monotherapy | Moderate | As above |
| Severe/psychotic depression | Add antipsychotic (e.g., olanzapine 5-10mg) | Strong (NICE recommended) | Metabolic parameters, EPS |
| Chronic GAD with panic | Combine SSRI + CBT with exposure | Strong | Adherence to exposure tasks |
🚩 Red Flag: Sudden improvement in mood after prolonged severe depression may indicate suicide planning (patient has made decision, feels relief). Requires immediate risk reassessment.
Key Take-Aways:
Essential Common Mental Disorders Numbers:
| Metric | Value | Clinical Significance |
|---|---|---|
| PHQ-9 treatment threshold | ≥10 | Moderate depression requiring intervention |
| GAD-7 diagnostic threshold | ≥10 | Probable GAD (89% sensitivity) |
| SSRI therapeutic window | 6-8 weeks | Minimum trial duration before switching |
| Depression continuation | 6-12 months | Post-remission to prevent relapse |
| Panic attack peak | <10 minutes | Discriminates from sustained anxiety |
Key Principles/Pearls:
Quick Reference:
| Scenario | First Action | Escalation Trigger |
|---|---|---|
| PHQ-9 10-15 (mild-moderate) | Guided self-help or SSRI | No improvement 6-8 weeks |
| PHQ-9 ≥20 (severe) | SSRI + high-intensity CBT | Suicidal ideation, psychosis, self-neglect |
| GAD-7 ≥10 | SSRI (sertraline 50mg) | Failure of 2 SSRIs at therapeutic doses |
| Recurrent panic attacks | SSRI (start low: 25mg sertraline) + CBT | Agoraphobic avoidance developing |
| Treatment resistance | Switch class or augment (mirtazapine/lithium) | Consider specialist referral after 3 failed trials |
Have doubts about this lesson?
Ask Rezzy, our AI tutor, to explain anything you didn't understand
Test your understanding with these related questions
A 27-year-old woman presents with amenorrhea, weight loss, and excessive exercise. Her BMI is 16 kg/m². She has bradycardia and hypotension. What is the most serious immediate risk?